Hematology Advisor
LightNews LightNews
banner
hematologyadvisor.bsky.social
Hematology Advisor
@hematologyadvisor.bsky.social
130 followers 140 following 210 posts
HematologyAdvisor.com is a trusted knowledge base of practical information and resources focused on hematology and critical care medicine.
Posts Replies Media Videos
hematologyadvisor.bsky.social
ZR2 produced high remission rates and durable survival in adults aged 75 years and older with newly diagnosed #DLBCL. Published in @bloodjournals.hematology.org.

https://bit.ly/4jEkCLv

#lymphoma #lymsm
ZR2 Regimen Achieves High Remission, Durable Survival in Older Adults With Newly Diagnosed DLBCL
Phase 2 study results showed zanubrutinib combined with rituximab and lenalidomide produced high remission rates and durable survival in older adults with newly diagnosed DLBCL.
bit.ly
January 17, 2026 at 7:18 PM
hematologyadvisor.bsky.social
Tycel J. Phillips, MD, of @cityofhope.bsky.social elucidates the research landscape of BTKis in #MCL, particularly its potential as a first-line treatment.

https://bit.ly/3ZiPcRy

#MantleCellLymphoma #lymsm
BTK Inhibitor Therapy Makes Inroads Into First-Line MCL
BTK inhibitors (BTKi) in mantle cell lymphoma (MCL) are examined by Tycel J. Phillips, MD, particularly as potential first-line therapy.
bit.ly
January 16, 2026 at 11:05 PM
hematologyadvisor.bsky.social
#Cancersurvivors living outside of metropolitan areas are significantly more likely to experience #chronicpain than urban survivors. Published in @jamanetworkopen.com and @cancertherapyadv.bsky.social.

https://bit.ly/3Ls50yi

#cancerpain
Rural Cancer Survivors More Likely Than Urban Survivors to Experience Chronic Pain
Cancer survivors living in rural areas are more likely to experience chronic pain than urban cancer survivors.
bit.ly
January 16, 2026 at 8:53 PM
hematologyadvisor.bsky.social
The @fda.gov has expanded the approval of Cablivi® to include treatment of pediatric patients 12 years and older with #aTTP, in combination with plasma exchange and immunosuppressive therapy. From @medicalprofref.bsky.social.

https://bit.ly/4aTlSbu

#TTPawareness #iTTP #thrombosis
Cablivi Approved for Pediatric Acquired Thrombotic Thrombocytopenic Purpura
The FDA expanded the approval of Cablivi to include pediatric patients 12 years and older with acquired thrombotic thrombocytopenic purpura.
bit.ly
January 15, 2026 at 8:48 PM
hematologyadvisor.bsky.social
Differences in TP53 status fundamentally altered early cellular responses to decitabine in a model of #myelodysplasticSyndrome. Published in @jcb.org and @rarediseaseadvisor.bsky.social.

https://bit.ly/4jDZYLL

#MDS
TP53 Status Shapes Early Decitabine Response in MDS Cells
Multiomics integration identified 31 candidate genes that may underlie early decitabine resistance and suggest sensitization strategies.
bit.ly
January 14, 2026 at 5:45 PM
hematologyadvisor.bsky.social
After a single infusion of fidanacogene elaparvovec, a majority of patients with #hemophiliaB reported that their impression of life with #hemophilia was “greatly improved” and demonstrated gains in health-related QoL measures. From @jthjournal.bsky.social.

https://bit.ly/49kPq0D
Patients With Hemophilia B Report Improvement in QoL After Gene Therapy
A majority of patients with hemophilia B reported that their impression of life with hemophilia was “greatly improved” after gene therapy with fidanacogene elaparvovec.
bit.ly
January 13, 2026 at 5:48 PM
hematologyadvisor.bsky.social
"I would like to see more #sicklecell comprehensive care teams become trauma-informed, given how repeatedly traumatizing the health care system has been for too many individuals with #SCD." Quote from Marsha Treadwell, PhD, of @ucsfhealth.bsky.social.

https://bit.ly/4raekGn

#sickleCellDisease
January 12, 2026 at 7:40 PM
hematologyadvisor.bsky.social
#Cancer patients and survivors are more likely to report housing and utility insecurity than those who do not have a history of cancer. Published in @cancertherapyadv.bsky.social.

https://bit.ly/49uvpmW

#HousingInsecurity
A History of Cancer Is Associated with Increased Risk for Housing Insecurity
Cancer patients and survivors are more likely to report housing and utility insecurity than those who do not have a history of cancer.
bit.ly
January 11, 2026 at 6:39 PM
hematologyadvisor.bsky.social
Live cell imaging-derived phenotypes reliably forecasted clinically relevant heterogeneity in chronic #lymphocyticLeukemia and delineated patient cohorts likely to respond to ruxolitinib, venetoclax, or their combination. Published in @cp-iscience.bsky.social.

https://bit.ly/3Z0pbq4

#CLL #leusm
Live Cell Phenotyping Stratifies CLL and Predicts Response to Targeted Therapy
Machine-learning analysis of untreated CLL samples identified 5 stable patient clusters associated with distinct therapeutic sensitivities.
bit.ly
January 10, 2026 at 7:18 PM
hematologyadvisor.bsky.social
A #machineLearning algorithm may be the optimal method for distinguishing beta #thalassemia subtypes, with greater accuracy than would be expected relying on clinical features alone.

https://bit.ly/49JIkTe
Machine Learning Algorithm Effectively Distinguishes Alpha Thalassemia Subtypes
Researchers determined a machine learning algorithm may be the optimal method for distinguishing beta thalassemia subtypes.
bit.ly
January 7, 2026 at 6:11 PM
hematologyadvisor.bsky.social
Diagnostic and treatment challenges for peripheral T-cell #lymphomas were identified, and potential solutions discussed at the Singapore Scientific Symposium 2024 by a panel of #lymphoma experts from across Asia. From @ascopost.bsky.social journal JCO Global Oncology.

https://bit.ly/3Nd3PDd

#lymsm
Challenges in PTCL Management Identified in Asia
Researchers identified several diagnostic and treatment challenges for patients with PTCLs in Asia.
bit.ly
January 6, 2026 at 5:46 PM
hematologyadvisor.bsky.social
The @pathologists.bsky.social published a guideline for the laboratory workup of #amyloidosis in the Archives of Pathology & Laboratory Medicine.

https://bit.ly/496t2I9
CAP Aims to Improve Early Diagnosis of Amyloidosis With New Guideline
The College of American Pathologists published a guideline for the laboratory workup of amyloidosis.
bit.ly
January 5, 2026 at 6:13 PM
hematologyadvisor.bsky.social
The @fda.gov has approved Fesilty™ for the treatment of acute bleeding episodes in pediatric and adult patients with #congenitalFibrinogenDeficiency, including hypo- or afibrinogenemia. From @medicalprofref.bsky.social.

https://bit.ly/4jfvYWc
FDA Approves Fesilty for Congenital Fibrinogen Deficiency
The FDA has approved Fesilty for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency.
bit.ly
January 4, 2026 at 6:48 PM
hematologyadvisor.bsky.social
Recombinant von Willebrand factor provides effective and reliable perioperative hemostatic control for adults with #vonWillebrandDisease.

https://bit.ly/3LiDG5r

#VWD
Real-World Data Support Effective Surgical Hemostasis With Recombinant VWF in Adults With VWD
Researchers determined rVWF provides effective and reliable perioperative hemostatic control for adults with VWD.
bit.ly
January 3, 2026 at 7:35 PM
hematologyadvisor.bsky.social
#FNAIT is a potentially life-threatening condition with a distinct subset of HPA-1a antibodies that can directly activate platelets through FcγRIIa. Presented at #ASH2025, from @rarediseaseadvisor.bsky.social.

https://bit.ly/4b8SlKS

#ASH25
Platelet-Activating Anti-HPA-1a Antibodies Drive Pathogenic Mechanisms in FNAIT
Only the M-204 anti-HPA-1a antibody triggered FcγRIIa-dependent platelet activation, indicating functional heterogeneity relevant to the severity of FNAIT.
bit.ly
January 2, 2026 at 8:50 PM
hematologyadvisor.bsky.social
The @fda.gov has granted accelerated approval to Lunsumio Velo™, a SC formulation of mosunetuzumab-axgb, for the treatment of adult patients with R/R #follicularLymphoma after 2 or more lines of systemic therapy. From @medicalprofref.bsky.social.

https://bit.ly/4qoYAP8

#lymsm
Lunsumio Velo Approved for SC Administration in R/R Follicular Lymphoma
FDA grants accelerated approval to subcutaneous mosunetuzumab-axgb for adults with relapsed or refractory follicular lymphoma after 2 therapy lines.
bit.ly
January 1, 2026 at 8:49 PM
hematologyadvisor.bsky.social
For patients with previously treated severe or nonsevere #hemophilia A, the effectiveness, safety, and tolerability of damoctocog alfa pegol were supported in an updated analysis of the real-world HEM-POWR study.

https://bit.ly/3YiRLTn
Updated Analysis Supports Damoctocog Alfa Pegol for Patients With Hemophilia A
Researchers determined damoctocog alfa pegol is safe and effective in patients with previously treated severe or nonsevere hemophilia A.
bit.ly
December 31, 2025 at 6:09 PM
hematologyadvisor.bsky.social
In a review published in @thelancethaem.bsky.social, Bingwen Eugene Fan, MBBS, of Tan Tock Seng Hospital, and colleagues issued a multidisciplinary call to embed #sustainability into #anticoagulation care.

https://bit.ly/4jeQo1y
Embedding Sustainability Into Anticoagulation Care
Researchers issued a multidisciplinary call to embed sustainability into anticoagulation care.
bit.ly
December 30, 2025 at 5:48 PM
hematologyadvisor.bsky.social
#AML highlights from #ASH2025 include results from the AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies. From @cancertherapyadv.bsky.social.

https://bit.ly/3LmS7Fx

#AcuteMyeloidLeukemia #leusm
ASH 2025: Refining Chemotherapy and Biomarker-Adapted Strategies in AML - Hematology Advisor
AML highlights from ASH 2025 include results from the AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.
bit.ly
December 29, 2025 at 4:47 PM
hematologyadvisor.bsky.social
Patients with chronic #lymphocyticLeukemia who discontinued covalent BTKi and later required BCL2i therapy faced diminishing clinical benefit, underscoring a pressing therapeutic gap. From @rarediseaseadvisor.bsky.social.

https://bit.ly/3MX8zg6

#CLL #leusm
Prognosis Worsens Once Patients Exhaust BTKi and BCL2i in CLL
Longitudinal data reveal consistent initial responsiveness to targeted agents but limited durability once patients cycle through both BTKi and BCL2i classes.
bit.ly
December 25, 2025 at 3:55 PM
hematologyadvisor.bsky.social
MRD is “a credible intermediate endpoint” for some patients with newly diagnosed acute myeloid #leukemia. Presented at #ASH25, covered by @cancertherapyadv.bsky.social.

https://bit.ly/4atbKWP

#AML #leusm
MRD Is “Credible” Surrogate Endpoint in Acute Myeloid Leukemia - Hematology Advisor
In the HARMONY Alliance Study of European randomized clinical trials, researchers sought to determine if MRD could serve as an intermediate endpoint in intensively treated AML.
bit.ly
December 23, 2025 at 5:54 PM
hematologyadvisor.bsky.social
Elranatamab treatment of patients with advanced immunoglobulin light-chain #amyloidosis resulted in a 100% overall response rate. Published in @bloodjournals.hematology.org.

https://bit.ly/4s4uSR7

#ALAmyloidosis
Elranatamab May Be Effective for Light Chain Amyloidosis
Researchers determined elranatamab may be an effective treatment for patients with advanced immunoglobulin light-chain amyloidosis and further study is warranted.
bit.ly
December 22, 2025 at 6:07 PM
hematologyadvisor.bsky.social
The @fda.gov has accepted for Priority Review the sBLA for nivolumab in combination with AVD for adult and pediatric patients aged 12 years and older with previously untreated stage III or IV classical #HodgkinLymphoma. From @medicalprofref.bsky.social.

https://bit.ly/48IiHls

#lymsm
FDA to Review Nivolumab Combo for First-Line Classical Hodgkin Lymphoma
The FDA has granted Priority Review to nivolumab in combination with AVD for patients aged 12 years and older with untreated stage III or IV cHL.
bit.ly
December 21, 2025 at 6:40 PM
hematologyadvisor.bsky.social
Adding enasidenib to venetoclax appears to be safe and effective in IDH2-mutated, R/R acute myeloid leukemia. Published in @thelancethaem.bsky.social.

https://bit.ly/4rXsICN

#AML #leusm
Enasidenib Is a Safe and Effective Intervention in IDH2-Mutated AML and MDS
Researchers determined Adding enasidenib to venetoclax appears to be safe and effective in patients with IDH2-mutated, relapsed or refractory AML.
bit.ly
December 20, 2025 at 8:12 PM
hematologyadvisor.bsky.social
Many families with children being treated for acute #lymphoblasticLeukemia face household material hardship and/or income loss. Presented at #ASH25, covered by @cancertherapyadv.bsky.social.

https://bit.ly/3L7JaQj

#ALL #leusm
Treating Pediatric ALL Can Lead to Household Income Loss, Financial Hardship - Hematology Advisor
Study researchers aimed to describe the cumulative incidence of financial toxicity among families with a child being treated for ALL, as well as the sociodemographic factors associated with the development of financial toxicity.
bit.ly
December 19, 2025 at 9:00 PM